Literature DB >> 29201237

MicroRNA-338-3p targets SOX4 and inhibits cell proliferation and invasion of renal cell carcinoma.

Zhigang Tong1, Xianfeng Meng1, Jinsong Wang1, Lixin Wang2.   

Abstract

MicroRNA (miR)-338-3p has been reported to be involved in tumor progression and development in various types of cancer. However, the biological function of miR-338-3p and its related molecular pathways involved in the progression of renal cell carcinoma (RCC) are unknown. The present study aimed to investigate the biological role and underlying mechanism of miR-338-3p in RCC cells. It was demonstrated that miR-338-3p expression level was significantly downregulated (P<0.05) in RCC tissues and cell lines. Clinical association analysis indicated that low expression of miR-338-3p was significantly associated with advanced TNM stage and lymph node metastasis (P<0.05). Function assays revealed that restoration of miR-338-3p in RCC cells significantly inhibited cell proliferation, colony formation, migration and invasion (P<0.05). Notably, sex-determining region Y-box 4 (SOX4) was identified as a direct target of miR-338-3p in RCC cells through a luciferase reporter assay, reverse transcription-quantitative polymerase chain reaction and western blot analysis. Furthermore, SOX4 overexpression partially rescued miR-338-3p-mediated inhibition of cell proliferation, colony formation, migration and invasion in RCC cells. These results suggested that miR-338-3p functioned as a tumor suppressor in RCC cells by modulating SOX4, suggesting that miR-338-3p may have a potential use in the treatment of RCC.

Entities:  

Keywords:  microRNA; microRNA-338-3p; proliferation; renal cell carcinoma; sex-determining region Y-box 4

Year:  2017        PMID: 29201237      PMCID: PMC5704281          DOI: 10.3892/etm.2017.5169

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  31 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma.

Authors:  Akira Kurozumi; Yusuke Goto; Atsushi Okato; Tomohiko Ichikawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2016-06-30       Impact factor: 3.172

3.  SOX4 overexpression is a novel biomarker of malignant status and poor prognosis in breast cancer patients.

Authors:  Guo-Dong Song; Yu Sun; Hong Shen; Wei Li
Journal:  Tumour Biol       Date:  2015-01-16

4.  SOX4 overexpression regulates the p53-mediated apoptosis in hepatocellular carcinoma: clinical implication and functional analysis in vitro.

Authors:  Wonhee Hur; Hyangshuk Rhim; Chan Kwon Jung; Jin Dong Kim; Si Hyun Bae; Jeong Won Jang; Jin Mo Yang; Seong-Taek Oh; Dong Goo Kim; Hee Jung Wang; Sean Bong Lee; Seung Kew Yoon
Journal:  Carcinogenesis       Date:  2010-04-16       Impact factor: 4.944

5.  Mammalian microRNAs predominantly act to decrease target mRNA levels.

Authors:  Huili Guo; Nicholas T Ingolia; Jonathan S Weissman; David P Bartel
Journal:  Nature       Date:  2010-08-12       Impact factor: 49.962

6.  miRNA-338-3p suppresses cell growth of human colorectal carcinoma by targeting smoothened.

Authors:  Kai Sun; Hai-Jun Deng; Shang-Tong Lei; Jing-Qing Dong; Guo-Xin Li
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

Review 7.  miRNAs in human cancer.

Authors:  Thalia A Farazi; Jessica I Spitzer; Pavel Morozov; Thomas Tuschl
Journal:  J Pathol       Date:  2010-11-18       Impact factor: 7.996

8.  Upregulated Expression of SOX4 Is Associated with Tumor Growth and Metastasis in Nasopharyngeal Carcinoma.

Authors:  Si Shi; Xiaolei Cao; Miao Gu; Bo You; Ying Shan; Yiwen You
Journal:  Dis Markers       Date:  2015-10-22       Impact factor: 3.434

9.  Upregulation of SOX4 antagonizes cellular senescence in esophageal squamous cell carcinoma.

Authors:  Rongfei Han; Shiying Huang; Yonghua Bao; Xin Liu; Xiaoyu Peng; Zhiguo Chen; Qian Wang; Jiaqi Wang; Qiuping Zhang; Tianfu Wang; Duo Zheng; Wancai Yang
Journal:  Oncol Lett       Date:  2016-06-29       Impact factor: 2.967

10.  Suppression of miR-204 enables oral squamous cell carcinomas to promote cancer stemness, EMT traits, and lymph node metastasis.

Authors:  Cheng-Chia Yu; Pei-Ni Chen; Chih-Yu Peng; Chuan-Hang Yu; Ming-Yung Chou
Journal:  Oncotarget       Date:  2016-04-12
View more
  7 in total

1.  LINC02738 Participates in the Development of Kidney Cancer Through the miR-20b/Sox4 Axis.

Authors:  Chao Han; Bin Xu; Lin Zhou; Long Li; Chao Lu; Guo-Peng Yu; Yu-Shan Liu
Journal:  Onco Targets Ther       Date:  2020-10-09       Impact factor: 4.147

Review 2.  Molecular interactions of miR-338 during tumor progression and metastasis.

Authors:  Meysam Moghbeli
Journal:  Cell Mol Biol Lett       Date:  2021-04-07       Impact factor: 5.787

3.  hsa_circ_0001018 promotes papillary thyroid cancer by facilitating cell survival, invasion, G1/S cell cycle progression, and repressing cell apoptosis via crosstalk with miR-338-3p and SOX4.

Authors:  Qiang Luo; Feng Guo; Qingfeng Fu; Guoqing Sui
Journal:  Mol Ther Nucleic Acids       Date:  2021-02-24       Impact factor: 8.886

4.  SPRR3, a novel miR-338-3p target, regulates the malignant progression of clear cell renal cell carcinoma in vitro via the PI3K/Akt signaling pathway.

Authors:  Man Wu; Qiaoyan Guo; Xianjun Liu; Linlin Wu
Journal:  Exp Ther Med       Date:  2022-03-08       Impact factor: 2.447

5.  Silver nanoparticles achieve cytotoxicity against breast cancer by regulating long-chain noncoding RNA XLOC_006390-mediated pathway.

Authors:  Lin Tao; Xi Chen; Jiawei Sun; Changjun Wu
Journal:  Toxicol Res (Camb)       Date:  2021-01-22       Impact factor: 3.524

6.  miR-363-3p Inhibits Osteosarcoma Cell Proliferation and Invasion via Targeting SOX4.

Authors:  Kejun Wang; Lin Yan; Fen Lu
Journal:  Oncol Res       Date:  2018-02-22       Impact factor: 5.574

7.  The Diagnostic Value of Serum Ang, VEGF, and CRP Combined with the Chinese Medicine Antitumor Formula in the Treatment of Advanced Renal Carcinoma.

Authors:  Nana Dong; Shengmin Zhang; Shuangjun Zhang; Qiongqiong Zhao; Donghua Zhang; Feng Chen
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-14       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.